Zurich, Switzerland, June 22, 2009 Covagen (CH) and Roche (CH) announced today that they have entered a collaboration agreement under which Covagen will use its protein engineering technology to isolate Fynomers – a novel class of protein-based drugs - binding to undisclosed targets provided by Roche. Fynomers delivered by Covagen will be further tested and evaluated by Roche to discover potential new treatments for patients with unmet medical needs. The financial terms of the collaboration agreement were not disclosed.
Dr. Julian Bertschinger, CEO and co-founder of Covagen commented: “We are proud to enter a collaboration with Roche, one of the leading science-based healthcare companies in the field of biopharmaceuticals.” Dr. Dragan Grabulovski, CSO and co-founder of Covagen added: “This collaboration with Roche represents a further step to establish Covagen’s Fynomers as new binding proteins for a variety of applications in drug discovery.”
